The Cooper Cos. (COO) Stake Raised by Eagle Asset Management Inc.

The Cooper Cos. (COO) Stake Raised by Eagle Asset Management Inc.

Eagle Asset Management Inc. raised its stake in The Cooper Cos. (NYSE:COO) by 2.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 152,446 shares of the medical device company’s stock after buying an additional 4,351 shares during the period. Eagle Asset Management Inc.’s holdings in The Cooper Cos. were worth $27,327,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in COO. Beacon Financial Group boosted its position in shares of The Cooper Cos. by 67.4% in the second quarter. Beacon Financial Group now owns 4,489 shares of the medical device company’s stock worth $762,000 after buying an additional 1,807 shares during the period. Fisher Asset Management LLC boosted its position in shares of The Cooper Cos. by 14.8% in the second quarter. Fisher Asset Management LLC now owns 106,914 shares of the medical device company’s stock worth $19,469,000 after buying an additional 13,800 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in shares of The Cooper Cos. by 2.6% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 17,615 shares of the medical device company’s stock worth $3,022,000 after buying an additional 440 shares during the period. TT International purchased a new position in shares of The Cooper Cos. during the second quarter worth about $2,072,000. Finally, British Columbia Investment Management Corp boosted its position in shares of The Cooper Cos. by 11.9% in the second quarter. British Columbia Investment Management Corp now owns 24,085 shares of the medical device company’s stock worth $4,132,000 after buying an additional 2,554 shares during the period. 94.19% of the stock is currently owned by institutional investors.

Shares of The Cooper Cos. (NYSE:COO) traded up 1.20% during trading on Friday, hitting $170.70. 376,622 shares of the stock were exchanged. The Cooper Cos. has a 52 week low of $119.28 and a 52 week high of $190.99. The firm has a market capitalization of $8.32 billion, a price-to-earnings ratio of 33.42 and a beta of 0.62. The stock’s 50 day moving average price is $176.62 and its 200 day moving average price is $175.54.

The Cooper Cos. (NYSE:COO) last announced its quarterly earnings results on Thursday, September 1st. The medical device company reported $2.30 EPS for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.01. The company had revenue of $514.70 million for the quarter. The Cooper Cos. had a net margin of 13.14% and a return on equity of 14.89%. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.97 earnings per share. On average, equities analysts predict that The Cooper Cos. will post $8.43 earnings per share for the current year.

COO has been the topic of a number of recent analyst reports. Stifel Nicolaus lifted their price objective on shares of The Cooper Cos. from $195.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, August 31st. Jefferies Group lifted their price objective on shares of The Cooper Cos. from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, August 24th. Zacks Investment Research raised shares of The Cooper Cos. from a “hold” rating to a “buy” rating and set a $198.00 price objective on the stock in a research note on Wednesday, October 5th. KeyCorp set a $221.00 price objective on shares of The Cooper Cos. and gave the company a “buy” rating in a research note on Saturday, October 1st. Finally, Wells Fargo & Co. reissued a “hold” rating on shares of The Cooper Cos. in a research note on Sunday, September 11th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $187.80.

In other news, Director William A. Kozy bought 270 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The shares were acquired at an average price of $186.69 per share, with a total value of $50,406.30. Following the acquisition, the director now owns 770 shares of the company’s stock, valued at approximately $143,751.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Albert G. White III sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $185.72, for a total transaction of $3,714,400.00. Following the sale, the executive vice president now directly owns 41,639 shares in the company, valued at approximately $7,733,195.08. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

The Cooper Cos. Company Profile

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Related posts

Leave a Comment